- Home
- EDTK vs CLRB Comparison
EDTK vs CLRB Comparison
Compare EDTK & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- CLRB
- Stock Information
- Founded
- EDTK 2013
- CLRB 2002
- Country
- EDTK China
- CLRB United States
- Employees
- EDTK N/A
- CLRB N/A
- Industry
- EDTK Other Consumer Services
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- CLRB Health Care
- Exchange
- EDTK Nasdaq
- CLRB Nasdaq
- Market Cap
- EDTK 14.7M
- CLRB 12.5M
- IPO Year
- EDTK 2020
- CLRB N/A
- Fundamental
- Price
- EDTK $0.88
- CLRB $7.90
- Analyst Decision
- EDTK
- CLRB Hold
- Analyst Count
- EDTK 0
- CLRB 2
- Target Price
- EDTK N/A
- CLRB N/A
- AVG Volume (30 Days)
- EDTK 6.5K
- CLRB 1.3M
- Earning Date
- EDTK 08-18-2025
- CLRB 08-12-2025
- Dividend Yield
- EDTK N/A
- CLRB N/A
- EPS Growth
- EDTK N/A
- CLRB N/A
- EPS
- EDTK N/A
- CLRB N/A
- Revenue
- EDTK $624,365.00
- CLRB N/A
- Revenue This Year
- EDTK N/A
- CLRB N/A
- Revenue Next Year
- EDTK N/A
- CLRB N/A
- P/E Ratio
- EDTK N/A
- CLRB N/A
- Revenue Growth
- EDTK N/A
- CLRB N/A
- 52 Week Low
- EDTK $0.80
- CLRB $6.50
- 52 Week High
- EDTK $1.27
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- EDTK 43.35
- CLRB 40.04
- Support Level
- EDTK $0.85
- CLRB $9.60
- Resistance Level
- EDTK $0.95
- CLRB $10.19
- Average True Range (ATR)
- EDTK 0.06
- CLRB 1.57
- MACD
- EDTK -0.00
- CLRB -0.50
- Stochastic Oscillator
- EDTK 22.28
- CLRB 11.58
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.